Skip to main content
Clinical Trials/KCT0000059
KCT0000059
Recruiting
未知

Multicenter, open-labeled, single-arm group trial for the interval of surveillance colonoscopy after polypectomy

Hanyang University Guri Hospital0 sites2,000 target enrollmentTBD
ConditionsNeoplasms

Overview

Phase
未知
Intervention
Not specified
Conditions
Neoplasms
Sponsor
Hanyang University Guri Hospital
Enrollment
2000
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Observational Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • patients who underwent polypectomy for adenomas during screening colonoscopy

Exclusion Criteria

  • Patients with advanced colon cancer, previous colon surgery, chronic inflammatory bowel disease, familial adenomatous polyposis, and those with refusal of consent to the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-resistant pellets in patients with cystic fibrosis suffering from pancreatic exocrine insufficiency.patients with cystic fibrosis suffering from pancreatic exocrine insufficiencyMedDRA version: 21.0Level: PTClassification code: 10079428Term: Cystic fibrosis gastrointestinal disease Class: 100000004850Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
CTIS2023-503256-27-00MEDA Pharma GmbH & Co. KG80
Active, not recruiting
Phase 1
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients with Spinal Muscular AtrophySpinal Muscular AtrophyMedDRA version: 20.1 Level: LLT Classification code 10051203 Term: Spinal muscular atrophy congenital System Organ Class: 100000004850Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2015-001589-25-PLF. Hoffmann-La Roche Ltd131
Active, not recruiting
Phase 1
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients with Spinal Muscular AtrophySpinal Muscular AtrophyMedDRA version: 20.1Level: LLTClassification code 10051203Term: Spinal muscular atrophy congenitalSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2015-001589-25-GBF. Hoffmann-La Roche Ltd131
Active, not recruiting
Phase 1
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients with Spinal Muscular AtrophySpinal Muscular AtrophyMedDRA version: 20.1Level: LLTClassification code 10051203Term: Spinal muscular atrophy congenitalSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2015-001589-25-BEF. Hoffmann-La Roche Ltd173
Active, not recruiting
Phase 1
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients with Spinal Muscular AtrophySpinal Muscular AtrophyMedDRA version: 20.1 Level: LLT Classification code 10051203 Term: Spinal muscular atrophy congenital System Organ Class: 100000004850Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2015-001589-25-DEF. Hoffmann-La Roche Ltd131